Company / Current Assets
Denali Therapeutics Inc. Current Assets History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$900.7M
FY2025
5-year range
$864.4M / $1.4B
FY2021-FY2025
Trend
+4.2%
vs FY2024
Sector context
#60 of 213
Health Care
What the data says
At $901M, Denali Therapeutics Inc.'s current assets ranks #60 of 213 in the Health Care sector. Current Assets returned to growth in FY2025 after 2 years of decline, reaching $901M.
Based on SEC 10-K filings.
$901M in FY2025 with a 5-year CAGR of -9.6%.
Declined from $1.1B to $901M over the past 2 years.
Health Care sector context is included.
Current Assets over time
Growth rates
- 3-Year CAGR
- -13.1%
- 5-Year CAGR
- -9.6%
- 10-Year CAGR
- -
Sector benchmark
#60 of 213 in Health CareTop 28% of 213This company $900.7M Sector average $2.5B
▼
-64.3% below sector average
Key checks
Key Insights
- 5-year CAGR of -9.6%, indicating a declining trend.
- In FY2025, current assets increased 4.2% year-over-year.
- Ranks #60 out of 213 companies in the Health Care sector.
- Peak current assets was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.73 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $900.7M | +4.2% |
| FY2024 | $864.4M | -18.8% |
| FY2023 | $1.1B | -22.5% |
| FY2022 | $1.4B | +52.9% |
| FY2021 | $897.2M | -40.0% |
| FY2020 | $1.5B | +247.8% |
| FY2019 | $430.0M | -10.6% |
| FY2018 | $480.8M | +17.4% |
| FY2017 | $409.6M | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026